US health authorities on Wednesday approved the new version of Pfizer and Moderna’s COVID-19 vaccines for the omicron variant, with a view to quickly launching a new immunization campaign.
The two updated vaccines were authorized for a booster dose, starting at 12 years of age, that of Pfizer and from the age of 18 modernThe US drug agency, the FDA, said in a statement.
The new generation of vaccines targets both the original strain of the COVID-19 as well as the subvariants BA.4 and BA.5 of ómicron.
Therefore, they should “provide greater protection against the currently circulating omicron variant”, the FDA wrote.
Earlier this summer, the US Department of Health announced that it had purchased 105 million doses of Pfizer and 66 million modern to wear during fall and winter.
Vaccines have not yet been recommended by the Centers for Disease Control and Prevention (CDC), the main US public health agency.
The CDC convened a committee of independent experts to discuss the issue on Thursday.
After carrying out these consultations, the director of the agency, Rochelle Walensky, will be in charge of giving it the definitive green light.
This new version of the immunizers could be available next week in the country.
The vaccines currently circulating were designed to protect against the initial strain of the virus that was first reported in late 2019 in Wuhan, China.
But little by little they have been less effective against the variants that appeared over time, due to the rapid evolution of the virus.
Unlike the alpha and delta variants, which eventually gave way, omicron and its sub-variants have gradually dominated infections in 2022 around the world.
Pfizer Y modern they have also submitted an authorization application for this updated version of their vaccine to the European Medicines Agency (EMA).